Filing identity and reporting period
Important source mismatch: The request identifies “Solana Co,” but the supplied 10-Q is for Helius Medical Technologies, Inc. (Nasdaq: HSDT), for the quarter ended September 30, 2022, filed November 14, 2022. The summary below reflects the filing text, not Solana Co.
Helius develops and commercializes PoNS, a non-implanted neurostimulation device. U.S. commercial sales began in April 2022; the product had been commercially available in Canada since 2019.
Financial results and liquidity
Amounts below are in U.S. dollars; income statement and cash-flow figures are in millions unless stated otherwise.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0.196 | $0.109 | $0.505 | $0.264 |
| Gross profit / margin | $0.095 / 48.5% | $0.023 / 21.1% | $0.192 / 38.0% | $0.095 / 36.0% |
| Operating loss | $(4.853) | $(4.373) | $(12.847) | $(14.040) |
| Net loss | $(1.030) | $(4.687) | $(9.186) | $(14.030) |
| Net loss per share, basic and diluted | $(0.12) | $(2.01) | $(0.52) | $(6.29) |
- Q3 revenue included $139,000 of U.S. product sales and $56,000 of Canadian sales. Nine-month product sales were $202,000 in the U.S. and $295,000 in Canada.
- Cash and cash equivalents were $16.658 million at September 30, 2022, versus $11.005 million at December 31, 2021. Working capital was $17.017 million, up from $9.941 million.
- Nine-month operating cash use was $12.167 million, compared with $9.925 million in the prior-year period. Investing cash use was $13,000; financing provided $17.869 million. Ending cash, cash equivalents and restricted cash were $16.688 million.
- Total liabilities were $5.898 million, including a $4.455 million derivative liability for warrants. The filing does not report conventional borrowings as a material balance-sheet item.
- Gross proceeds from the August 2022 offering were $18 million; the company reported approximately $16.3 million in net proceeds. It issued 24 million common shares and warrants to purchase 36 million additional shares.
Material changes versus the prior comparable period
- Nine-month revenue rose $241,000, largely reflecting U.S. product sales following the launch; product sales increased from $242,000 to $497,000.
- Nine-month operating expenses declined $1.096 million, though Q3 operating expenses increased $552,000 year over year. The Q3 increase included a $757,000 goodwill impairment and higher stock-based compensation.
- Nine-month net loss narrowed by $4.844 million. This improvement included a $5.489 million noncash gain from the reduction in the fair value of the new warrant liability; it should not be read as an equivalent improvement in underlying operating performance.
- Operating cash use increased by $2.242 million. The company attributed the increase primarily to reductions in accounts payable and accrued liabilities.
- The August offering substantially increased the share count: 28.2 million shares were outstanding at quarter-end, versus 3.8 million at year-end 2021. The 36 million public warrants create potential additional dilution.
Outlook, risks and unusual items
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year after filing. The company expects continued operating losses and cash outflows and reported $0.5 million of nine-month commercial product revenue.
- Cash runway and funding: Management expected available resources, including offering proceeds, to fund operations into the third quarter of 2023. Additional equity or debt financing would be needed thereafter; management cautioned that funding may not be available on acceptable terms. A planned stroke clinical trial also requires additional funding.
- Commercialization and reimbursement: PoNS was not covered by CMS or reimbursed by U.S. third-party payors. The company expected self-pay patients to be a primary source of sales before coverage is obtained and estimated broad government and commercial payer coverage could take at least 24 months. It planned further CMS engagement in the second half of 2023.
- Operational risks: The filing cites manufacturing and supply-chain constraints, labor shortages, inflation, higher interest rates, COVID-19 effects, competition for staff, and dependence on suppliers. These could delay product availability, regulatory work and commercialization.
- Warrants and unusual accounting: Public warrants were classified as a derivative liability. Their fair value fell from $9.9 million at issuance to $4.5 million at quarter-end, generating a $5.5 million noncash gain. The offering also produced $919,000 of interest expense related to the warrant accounting and allocated issuance costs.
- Goodwill and other matters: A post-offering decline in the share price triggered an impairment test; a $757,000 charge reduced goodwill to zero. The company reported no material legal proceedings and stated that disclosure controls were effective.
Key facts for investors to verify
- Confirm the issuer: the supplied filing is Helius Medical Technologies, Inc., not Solana Co.
- Assess the cash runway against operating cash use and the stated need for new financing after the expected third-quarter 2023 runway.
- Track PoNS sales growth, U.S. launch economics, reimbursement progress and the timing and costs of planned clinical trials.
- Review the potential dilution and accounting volatility from the 36 million public warrants, including their terms and fair-value changes.
- Separate recurring operating performance from noncash warrant gains, stock-based compensation and the goodwill impairment when evaluating reported losses.